Trial record 1 of 1 for:    NCT01533948
Previous Study | Return to List | Next Study

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Roswell Park Cancer Institute
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Roswell Park Cancer Institute Identifier:
First received: January 18, 2012
Last updated: September 10, 2014
Last verified: September 2014

January 18, 2012
September 10, 2014
December 2011
September 2014   (final data collection date for primary outcome measure)
Overall response rate (complete response + partial response) to axitinib as assessed using RECIST version 1.1 [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01533948 on Archive Site
  • Toxicity of axitinib as a single agent as assessed by the severity of adverse effects by NCI CTCAE version 4 [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Progression-free survival [ Time Frame: From the date of study enrollment to the first observation of progressive disease or death, assessed up to 1 year ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: From the date of study enrollment to the time of death from any cause, assessed up to 1 year ] [ Designated as safety issue: No ]
  • Change in response as a function of standardized uptake value (SUV) readings and circulative tumor cells (CTC) by FLT-PET [ Time Frame: Baseline and 4 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma

This phase II trial studies how well axitinib works in treating patients with melanoma that is metastatic or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth


I. To determine the overall response rate (ORR) to axitinib in advanced melanoma. This will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.


I. Evaluate toxicity of axitinib as a single agent. II. Determine progression-free survival and overall survival. III. Explore the utility of 3'-deoxy-3'-[18F]fluorothymidine-labeled positron emission tomography (FLT-PET) as a predictive marker for response and compare to standard radiographic imaging.


I. Examine the prognostic and predictive significance of circulating melanoma tumor cells.

II. To examine whether functionally relevant polymorphisms in axitinib-related genes (vascular endothelial growth factor receptor [VEGFR] 1, VEGFR2 and VEGFR3) correlate with efficacy and toxicity of axitinib in advanced melanoma.


Patients receive axitinib orally (PO) twice daily (BID). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Recurrent Melanoma
  • Stage IIIA Melanoma
  • Stage IIIB Melanoma
  • Stage IIIC Melanoma
  • Stage IV Melanoma
  • Drug: axitinib
    Given PO
    Other Names:
    • AG-013736
    • Inlyta
  • Other: laboratory biomarker analysis
    Correlative studies
  • Other: pharmacogenomic studies
    Correlative studies
    Other Name: Pharmacogenomic Study
  • Other: 3'-deoxy-3'-[18F]fluorothymidine
    Correlative studies
    Other Name: 18F-FLT
  • Procedure: positron emission tomography
    Correlative studies
    Other Names:
    • FDG-PET
    • PET
    • PET scan
    • tomography, emission computed
Experimental: Treatment (enzyme inhibitor)
Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
  • Drug: axitinib
  • Other: laboratory biomarker analysis
  • Other: pharmacogenomic studies
  • Other: 3'-deoxy-3'-[18F]fluorothymidine
  • Procedure: positron emission tomography
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

Histologically or cytologically proven melanoma that is advanced (metastatic) or unresectable Measurable disease No more than one prior regimen (0-1) of chemotherapy or immunotherapy for metastatic or recurrent disease; therapy (chemotherapy, immunotherapy or radiotherapy) administered in the neo-adjuvant or adjuvant setting for previously localized disease is permitted, provided it was completed more than 3 months prior to enrollment; palliative radiotherapy is permitted provided it is completed >= 2 weeks prior to study therapy initiation and there is at least one measurable lesion outside the radiation field; at least 2 weeks since the end of prior systemic treatment, radiotherapy, or surgical procedure with resolution of all treatment-related toxicity to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Grade =< 1 or back to baseline except for alopecia or hypothyroidism Eastern Cooperative Oncology Group (ECOG) Performance Status of =< 2 Life expectancy >= 12 weeks Absolute neutrophil count (ANC) >= 1500 cells/mm^3 Platelets >= 75,000 cells/mm^3 Hemoglobin >= 9.0 g/dL Creatinine =< 1.5 X upper limit normal (ULN) or calculated creatinine clearance >= 60 mL/min Bilirubin =< 1.5 X ULN Transaminase =< 2.5 X ULN (for documented liver metastases, transaminase up to 5 X ULN is permitted) Random Urinary protein/creatinine ratio < 2 Have the ability to swallow and retain oral medication No evidence of preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart; the baseline systolic blood pressure readings must be =< 140 mm Hg, and the baseline diastolic blood pressure readings must be =< 90 mm Hg; patients whose hypertension is controlled by antihypertensive therapies are eligible Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment and for 6 months following completion of study treatment Patient or legal representative must understand the investigational nature of this study and sign an Institutional Review Board (IRB) approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

Prior anti-angiogenic therapy Major surgery < 4 weeks or radiation therapy < 2 weeks of starting the study treatment; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least 1 measurable lesion that has not been irradiated Significant history of bleeding events (e.g., hemoptysis, Grade 3 or Grade 4 gross hematuria) within 6 months prior to registration Presence of serious non-healing wounds, ulcers (including gastro-intestinal) and bone fractures

Gastrointestinal abnormalities including:

  • Inability to take oral medication
  • Requirement for intravenous alimentation
  • Prior surgical procedures affecting absorption including total gastric resection; segmental small bowel or colon resection is permitted
  • Treatment for active peptic ulcer disease in the past 6 months
  • Active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 6 months without evidence of resolution documented by endoscopy or colonoscopy
  • Malabsorption syndromes
  • History of gastrointestinal (GI) perforation within prior 12 months Current use or anticipated need for treatment with drugs that are known potent Cytochrome P450 3A4 (CYP3A4) inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir and delavirdine) Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, and St. John's wort) Requirement of therapeutic anticoagulant therapy with oral vitamin K antagonists; low-dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed; therapeutic use of low molecular weight heparin (or similar parenteral drug) for venous-thromboembolic disease is allowed Active seizure disorder or evidence of untreated brain metastases, spinal cord compression, or carcinomatous meningitis; patients with brain metastases that have been stable for >= 4 weeks by radiographic documentation following definitive therapy will be permitted provided this is not the only site of metastatic disease Arterial thrombotic events within 6 months of registration, including myocardial infarction, unstable angina or angina requiring medical or surgical intervention in the past 6 months, coronary/peripheral artery bypass graft, cerebrovascular accident, transient ischernic attack and clinically significant peripheral vascular disease (i.e., claudication on less than 1 block) Current congestive heart failure (New York Heart Association [NYHA] Class II, III or IV) Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness History of a malignancy except those treated with curative intent for skin cancer (other than melanoma), in-situ breast or in-situ cervical cancer, or those treated with curative intent for any other cancer with no evidence of disease for 3 years Female patients who are pregnant or lactating Received an investigational agent within 30 days prior to enrollment A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment Any condition which in the Investigator's opinion would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
18 Years and older
United States
I 197811, NCI-2011-03037
Roswell Park Cancer Institute
Roswell Park Cancer Institute
  • National Cancer Institute (NCI)
  • National Comprehensive Cancer Network
  • Pfizer
Principal Investigator: Nikhil Khushalani Roswell Park Cancer Institute
Roswell Park Cancer Institute
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP